Table 2.
Overview of clinical characteristics and the number of somatic mutations in tumour DNA and cfDNA
| Sample ID | Stage | PFS time | Post-surgery CRT | Blood drawing time | Number of somatic mutations | ||
|---|---|---|---|---|---|---|---|
| Tumour | Pre-surgery | Post-surgery | |||||
| ESCC01 | PT2N0M0G2–3 IIA | 5 m | N | 2d | 12 | 6 | 0 |
| ESCC02 | PT3N0M0G2 IIB | N | N | 3-4 h | 13 | 2 | 0 |
| ESCC03 | PT2N0M0G2 IIA | N | N | 3-4 h | 13 | 0 | 0 |
| ESCC04 | PT3N0M0G2 IIA | N | N | 3-4 h | 17 | 6 | 0 |
| ESCC05 | PT3N0M0G1 IIA | N | N | 9d | 9 | 1 | 0 |
| ESCC06 | PT3N0M0G2 IIA | N | N | 5d | 3 | 0 | 0 |
| ESCC07 | PT3N0M0G1 IIA | 12 m | Y | 3-4 h | 3 | NA | 1 |
| ESCC08 | PT3N1M0G1 IIIB | N | N | 3-4 h | 9 | 3 | 0 |
| ESCC09 | PT4aN0M0G2 IIIB | N | N | 3-4 h | 10 | 8 | 0 |
| ESCC10 | PT4aN0M0G2 IIIB | N | N | 9d | 20 | 16 | 0 |
| ESCC11 | PT3N1M0G3 IIIB | 4 m | N | 3-4 h | 5 | NA | 0 |
| ESCC12 | PT3N1M0G2 IIIB | N | Y | 3-4 h | 2 | 0 | 0 |
| ESCC13 | PT3N1M0G2 IIIB | N | Y | 3-4 h | 2 | 0 | 0 |
| ESCC14 | PT2N1M0G2 IIIA | N | Y | 6d | 13 | 4 | 1 |
PFS Progression-free survival, N no progression during follow-up, m months, CRT Chemoradiotherapy, NA Not Available